Abstract Number: 1078 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Awareness in Patients with Rheumatic Diseases: A Case-Control Study
Background/Purpose: Cardiovascular diseases are among the most common comorbidities in patients with rheumatic diseases (RD) and leads them to an overall increase of mortality in…Abstract Number: 1079 • 2019 ACR/ARP Annual Meeting
Assessing Psoriatic Arthritis Treatment Trends and Patient Journeys Between 2012 and 2018
Background/Purpose: Many new PsA treatments have emerged without clear guidelines on which therapy to use initially. We describe PsA treatment trends and patient journeys between…Abstract Number: 1080 • 2019 ACR/ARP Annual Meeting
Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience
Background/Purpose: Biosimilars hold the potential to improve access to needed therapies at a reduced cost. In Canada, biosimilar etanercept (bsETA-Brenzys® and Erelzi®) were recently approved…Abstract Number: 1081 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) share many clinical features but are differentiated by key clinical and molecular characteristics. Patients…Abstract Number: 1082 • 2019 ACR/ARP Annual Meeting
Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea
Background/Purpose: The aim of this study is to determine the risk of overall malignancy and site-specific cancer in ankylosing spondylitis (AS) patients compared with patients…Abstract Number: 1083 • 2019 ACR/ARP Annual Meeting
Patient Reported Outcomes over Time in 25,988 Axial Spondyloarthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Clinical Practice – Is PRO Remission Achieved? Results from the EuroSpA Collaboration
Background/Purpose: Treatment effectiveness in patients with axial spondylarthritis (axSpA) is evaluated by a combination of objective markers of disease activity and patient reported outcomes (PROs),…Abstract Number: 1084 • 2019 ACR/ARP Annual Meeting
Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have vastly improved prognosis in patients with axial spondyloarthritis (axSpA). However, many patients treated with TNFi still fail to…Abstract Number: 1085 • 2019 ACR/ARP Annual Meeting
Probiotic Use and Psoriatic Arthritis Disease Activity
Background/Purpose: Probiotics have been hypothesized to mediate inflammation through gut microbiome modulation, and growing evidence has suggested that our intestinal gut microbiome may play a…Abstract Number: 1086 • 2019 ACR/ARP Annual Meeting
Psoriatic Arthritis – Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis
Background/Purpose: Psoriasis (PsO) is a systemic inflammatory disease accompanied by comorbidities such as depression, cardiovascular diseases or metabolic syndrome. Approximately 10 - 27% of PsO…Abstract Number: 1087 • 2019 ACR/ARP Annual Meeting
Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)
Background/Purpose: Golimumab (GLM) has shown its efficacy and tolerability in various randomized clinical trials. Systemic data for GLM regarding health-economic parameters in daily clinical practice…Abstract Number: 1088 • 2019 ACR/ARP Annual Meeting
Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with psoriatic arthritis (PsA), but some patients switch to a different TNFi because of adverse…Abstract Number: 1089 • 2019 ACR/ARP Annual Meeting
Causes of Death in ANCA-Associated Vasculitis According to ANCA Type
Background/Purpose: Survival has improved in ANCA-associated vasculitis (AAV) with evolving management strategies, but patients remain at an increased risk of death compared to the general…Abstract Number: 1090 • 2019 ACR/ARP Annual Meeting
Identification of a Distinct Intestinal Behçet’s Disease Cluster in Japan: A Nationwide Retrospective Observational Study
Background/Purpose: Background: Behçet’s disease (BD) patients with poor prognoses must be identified to receive individualized care. Purpose: This study aimed to identify a subgroup of…Abstract Number: 1091 • 2019 ACR/ARP Annual Meeting
Risk of Preterm Birth by Timing of Lupus Diagnosis Among Women in the Georgia Lupus Registry
Background/Purpose: Women with systemic lupus erythematosus (SLE) are at a greater risk of having a preterm birth than the general population. Most studies examine preterm…Abstract Number: 1092 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Dose Adjustment Based on Patients’ Body Size in Low Dose Intravenous CYC Treatment for Rheumatic Diseases
Background/Purpose: Intravenous (IV) CYC in combination with glucocorticoids is a widely used induction therapy for severe cases of rheumatic diseases such as SLE, SSc, DM…
ACR Meeting Abstracts